参考资料--东紫苏的粗提及其粗提物抗HCV活性研究.docVIP

东紫苏的粗提及其粗提物抗HCV活性研究 摘 要 丙型肝炎病毒（Hepatitis C virus, HCV）属于黄病毒科，肝炎病毒属，有包膜单股正链RNA病毒。据估计，全世界约有1.7亿人感染HCV，感染人数不断增加，危害日益严重。HCV一经感染，约80%的病例会建立慢性感染，其中20%慢性感染者最终会发展成为肝硬化、肝癌。目前对丙型肝炎的治疗，主要采用聚乙二醇化干扰素（Peg-IFN）和利巴韦林(Ribavirin, RBV)联合疗法，但至少有约50％患者不能产生持续病毒学应答(SVR)，1型HCV感染患者SVR率更低。同时，联合疗法还存在服用吸收率低、毒副作用大和成本偏高等缺点，因此迫切需要建立更为完善的药物筛选方法，筛选新的抗HCV药物。 从植物中获得天然活性产物，具有良好的抗病毒活性及较轻的不良反应，是寻找新的HCV治疗药物的来源。东紫苏（Elsholtiza bodinieri Vaniot）为唇形（Lamiaceae）香薷属（Elsholtzia）植物，全草入药，味辛，性平。有发散解表、清热利湿、理气和胃的功能。用于外感风寒、感冒发热、头疼身痛、咽喉痛、虚火牙痛、消化不良、急性结膜炎、尿闭及肝炎等症。本研究拟对东紫苏粗提物进行抗HCV活性研究，为抗HCV药物提供了一个新的方向，为东紫苏的开发利用奠定基础。 关键词： 丙型肝炎病毒，东紫苏，粗提物，活性 ABSTRACT Hepatitis C virus (HCV), a small and enveloped RNA virus, was classifiedto Hepacivirus genus of Flaviviridae family. Its genome was a single- stranded positive-sense RNA of 9.6 kb length. It was estimated that 170 million people was infected with HCV worldwide.The increasing of infection case indicated the more severe prevalence. Once the occurrence of HCV infection, about 80% infected individuals will progressed to chronic disease. Among them, about 20% ended with liver failure and hepatocellular carcinoma. The current standard therapy was pegylated interferon-α and ribavirin combined treatment. However, less than 50% patients was shown with a sustained viral response (SVR), the effection of treatment is much poor in patients with HCV 1b strains infection. In addition, the low effection rate, the obvious side effects and high cost had hampered its clinical application.It was urgent to develop the new treatment using the more convincing anti-HCV drug screening system. Bioactive Natural Products from plants , with good antiviral activity and lLesser adverse reactions , is looking for new sources of HCV therapy . East basil (Elsholtiza bodinieri Vaniot) for the lip ( Lamiaceae ) Elsholtzia is to ( Elsholtzia ) plants, whole plant medicine , pungent flavor, neutral in nature. The function of divergence of the table, heat and dampness, clearing heat and pro